trending Market Intelligence /marketintelligence/en/news-insights/trending/ejovt9gue0i-fgoch4tu8q2 content esgSubNav
In This List

Novus Therapeutics postpones common stock offering

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Novus Therapeutics postpones common stock offering

Novus Therapeutics Inc. said it will postpone its common stock offering due to market conditions, including valuation sensitivity at the current share price.

The Irvine, Calif.-based company was planning to offer 6 million common shares.

Novus, which develops products for disorders of the ear, nose and throat, said its current cash will be sufficient for several business activities in 2019, including completion of phase 1 trials of its drug OP-02 to treat otitis media, a painful ear infection.

As of June 30, the company had $19.2 million in cash and cash equivalents.